Nanjungarh is under OAI – not escalated to warning letter – resolution halted due to movement restrictions for physical inspection; plant is running at full operating capacity (except 2.5months when the plant was shut) – there is need to increase the capacity – would be debottleneck the 30% more capacity in next 2 yrs – planning another greenfield capacity
(3) Generics (24% of FY21 rev) – Generics business has a benefit of Vertical integration via its own APIs business. The company has selected strategic product portfolio enabling presence in molecules with low competition. Going forward, the company is exploring additional manufacturing sites through partnerships and inorganic expansion. To further expand the non- US market, JPL plans to o launch 45 products in US and 27 products in Non-US market during FY22-FY26. New products are expected to generate an additional potential revenue of more than US $300 Mn during FY22-FY26
(4) Jubilant Biosys - CRDS (5% of rev) – JPL provides new Drug Discovery services to global innovators in US, EU, Japan & APAC. It is Fully integrated Drug Discovery service provider as well as functional specialist for complex chemistry, computational chemistry and scaleup up to GMP phase 1. For future growth, the company is expanding capacity & capability in Greater Noida & Bengaluru in addition to increasing research delivery efficiencies and identifying new customer targets.
*_Jubilant Therapeutics_* - was launched in 2019. Programs incubated inside Jubilant for 3+ years prior to company launch. It is transitioning to clinical stage in 6-9 months; next two IND filings by Q1FY23. * The Company is working towards creating shareholder value in this business through pharma/biotech partnerships and private / public equity raise during coming 18-24 months*
(3) Generics (24% of FY21 rev) – Generics business has a benefit of Vertical integration via its own APIs business. The company has selected strategic product portfolio enabling presence in molecules with low competition. Going forward, the company is exploring additional manufacturing sites through partnerships and inorganic expansion. To further expand the non- US market, JPL plans to o launch 45 products in US and 27 products in Non-US market during FY22-FY26. New products are expected to generate an additional potential revenue of more than US $300 Mn during FY22-FY26
(4) Jubilant Biosys - CRDS (5% of rev) – JPL provides new Drug Discovery services to global innovators in US, EU, Japan & APAC. It is Fully integrated Drug Discovery service provider as well as functional specialist for complex chemistry, computational chemistry and scaleup up to GMP phase 1. For future growth, the company is expanding capacity & capability in Greater Noida & Bengaluru in addition to increasing research delivery efficiencies and identifying new customer targets.
*_Jubilant Therapeutics_* - was launched in 2019. Programs incubated inside Jubilant for 3+ years prior to company launch. It is transitioning to clinical stage in 6-9 months; next two IND filings by Q1FY23. * The Company is working towards creating shareholder value in this business through pharma/biotech partnerships and private / public equity raise during coming 18-24 months*